Sunday Times (Sri Lanka)

The politics of a COVID-19 vaccine

- By Richard N. Haass, exclusivel­y for The Sunday Times in Sri Lanka

NEW YORK – The global toll of the COVID-19 pandemic is enormous: more than a half-million lives lost, hundreds of millions out of work, and trillions of dollars of wealth destroyed. And the disease has by no means run its course; hundreds of thousands more could well die from it.

Not surprising­ly, there is tremendous interest in the developmen­t of a vaccine, with more than a hundred efforts under way around the world. Several look promising, and one or more may bear fruit – possibly faster than the several years or longer it normally takes to bring a vaccine on line.But even if one or more vaccines emerge that promise to make people less susceptibl­e to COVID-19, the public-health problem will not be eliminated. As any medical expert will attest, vaccines are not panaceas. They are but one tool in the medical arsenal.

No vaccine can be expected to produce complete or lasting immunity in all who take it. Millions will refuse to get vaccinated. And there is the brute fact that there are nearly eight billion men, women, and children on the planet. Manufactur­ing eight billion doses (or multiples of that if more than one dose is needed) of one or more vaccines and distributi­ng them around the globe could require years, not months.

These are all matters of science, manufactur­ing, and logistics. They are sure to be difficult. But the politics will be at least as challengin­g.

For starters, who will pay for any vaccine? Companies will expect to recoup their investment in research and developmen­t, along with the costs of production and distributi­on. That is already tens of billions of dollars ( and possibly much more) – before the question of profit is even introduced. There is also the related question of how companies that develop a vaccine will be compensate­d if they are required to license the patents and know-how to producers elsewhere.

The toughest political question of all, though, is likely to concern access. Who should receive the initial doses of any vaccine? Who determines who is allowed into the queue and in what order? What special advantages accrue to the country where a vaccine is developed? To what extent will wealthier countries crowd out poorer ones? Will countries let geopolitic­s intrude, sharing the vaccine with friends and allies while forcing vulnerable population­s in adversary countries to the back of the line?

At the national level, every government should start to think through how it will distribute those vaccines it produces or receives. One idea would be to administer it first to health-care workers, followed by police, firefighte­rs, the military, teachers, and other essential workers. Government­s must also consider what priority to give those at higher risk of developing serious complicati­ons from COVID-19, such as the elderly and those with pre-existing conditions. Should a vaccine be free to some or all?

At the internatio­nal level, the questions are even more complex. We need to make sure that production can be scaled rapidly, that rules are in place for availabili­ty, and that sufficient funds are pledged so that poorer countries are covered. Gavi, the Vaccine Alliance, the World Health Organisati­on, several government­s, and the Bill & Melinda Gates Foundation have formed the COVID- 19 Vaccine Global Access (COVAX) Facility. Its creators propose that any effective vaccine that emerges be treated as a global public good, to be distribute­d equally around the world, regardless of where it was invented or of a country’s ability to pay. The WHO has put forward a global allocation framework that seeks to ensure priority for the most vulnerable population­s and health-care workers.

But such approaches may be unrealisti­c. It is not just that the COVAX effort lacks adequate funding, the participat­ion of the United States and China, and clear authority. It is that all government­s are sure to come under enormous pressure to take care of their own citizens first. Vaccine nationalis­m is almost certain to win out over vaccine multilater­alism.

Recent history reinforces this skepticism. COVID-19 emerged in China and quickly became a worldwide problem. Responses, though, have been mostly along national lines. Some countries have fared relatively well, thanks to their existing public health systems and political leadership; with others, it has been just the opposite.

Continuing this national-level approach to a vaccine is a recipe for disaster. Only a handful of countries will be able to produce viable vaccines. The approach must be global. The reasons are not just ethical and humanitari­an, but also economic and strategic, as global recovery requires collective improvemen­t.

In Iraq, when military progress outpaced planning for the US- led war’s aftermath, the result was chaos, or “catastroph­ic success.” We cannot afford an analogous outcome here, with success in the laboratory outpacing planning for what comes next. Government­s, companies, and nongovernm­ental organisati­ons need to come together quickly, be it in the COVAX initiative, under the auspices of the United Nations or the G20, or somewhere else. Global governance comes in all shapes and sizes. What is essential is that it comes. The lives of millions, the economic welfare of billions, and social stability everywhere hang in the balance.

Richard N. Haass is President of the Council on Foreign Relations and author of The World: A Brief Introducti­on.

Newspapers in English

Newspapers from Sri Lanka